Specimen / Container (สิ่งส่งตรวจ/ภาชนะ):
EDTA Bone marrow 3 ml, 1 tube, Lavender Top
For BH: Consent for Genomic Medicine Testing
For B2B: Molecular oncology test request form, Please click LINK
Useful For (ประโยชน์การทดสอบ):
Oncomine Myeloid DNA assay is a next-generation sequencing (NGS)-based assay designed for comprehensive molecular profiling of myeloid malignancies, enabling the detection of clinically relevant genetic alterations associated with disease diagnosis, classification, prognosis, and therapeutic decision-making.
The assay detects single nucleotide variants (SNVs) and small insertions/deletions (InDels) across 52 genes implicated in a broad spectrum of myeloid neoplasms from bone marrow, including:
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Chronic Myelomonocytic Leukemia (CMML)
Other hematologic malignancies with myeloid involvement
The identification of clinically significant and actionable genomic alterations can assist in:
Supporting the molecular diagnosis of myeloid malignancies
Disease classification and risk stratification according to current clinical guidelines
Prognostic assessment based on established molecular biomarkers
Selection of targeted therapies and personalized treatment strategies
Monitoring disease progression and informing long-term disease management
Gene List
DNA Hotspot Genes (32)
ABL1, ANKRD26, BRAF, CBL, CSF3R, DNMT3A, ETNK1, FLT3, GATA1, GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, MYD88, NPM1, NRAS, PPM1D, PTPN11, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAT3, STAT5B, U2AF1, UBA1, WT1
Full Gene Coverage (20)
ASXL1, BCOR, BCORL1, CALR, CEBPA, DDX41, ETV6, EZH2, IKZF1, NF1, PHF6, PRPF8, RAD21, RB1, RUNX1, SH2B3, STAG2, TET2, TP53, ZRSR2